Mumbai: Pharma company Lupin today said it has settled a litigation relating to Desloratadine tablets, a generic version of Schering-Plough’s Clarinex tablets.
“The settlement with Schering-Plough leaves us strategically poised to further strengthen, consolidate and grow our market position in US,” Lupin managing director Dr Kamal Sharma said in a statement.
As per terms of the settlement, Lupin could launch Desloratadine products on 1 July 2012 or earlier in certain circumstances, it said.
Lupin had filed a certification in the US to launch Desloratadine products contesting the validity of the patents. Subsequently, Schering Corp had filed a litigation against Lupin.
Clarinex registered sales of $329 million in 2007-08.
“The settlement, recent product approvals and growth in filings across markets are a testament to our increased strengths and focus on R&D and the quality of our intellectual property--a testimony to Lupin’s larger goal of developing and delivering quality, cost-effective drugs for everybody,” he said.
Lupin shares on BSE closed at Rs552.05, down 4.22%.